Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · HARVARD BIOSCIENCE INC (HBIO)

Harvard Bioscience shareholders approve 400,000-share increase to incentive plan

Neutral Impact 2 of 5 shareholder Written later

At its June 2, 2026 annual meeting, Harvard Bioscience stockholders approved an amended 2021 Incentive Plan that adds 400,000 shares for awards, and they approved an amendment to the Employee Stock Purchase Plan that increases its authorized shares. Stockholders also re-elected two directors, John Duke and Katherine A. Eade, to terms running to 2029, and ratified Grant Thornton LLP as auditor for 2026. The filing reports no financial results.

Key points

  • The incentive plan increase adds 400,000 shares; 646,520 shares were available for future awards as of December 31, 2025.
  • Votes for the incentive plan were 1,131,261, against were 680,030, and abstentions were 17,700.
  • John Duke and Katherine A. Eade were elected as Class II Directors for three-year terms ending in 2029.
  • Grant Thornton LLP was ratified as independent registered public accounting firm for fiscal 2026 with 2,781,705 votes for.

The filing

CompanyHARVARD BIOSCIENCE INC (HBIO)
Form8-K, current report
Filed with the SECJun 2, 2026, 4:01 PM ET
Accession number0001171843-26-003877

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.